Second, we determined the apoptotic effect of combining encorafenib with the recently developed BCL2/BCLXL inhibitor AZD4320 [33], and its drug dendrimer conjugate AZD0466, designed to minimise toxicity by gradually releasing AZD4320 by hydrolysis thus resulting in lower peak plasma levels, as well as through increased dendrimer retention within the tumour [21]. This evidence concerns the gene BCL2L1 and neoplasm.